Vitiligo is a chronic autoimmune disease resulting in skin depigmentation and reduced quality of life. There is no approved treatment for vitiligo repigmentation and current off-label therapies have limited efficacy, emphasising the need for improved treatment options. We investigated the therapeutic potential of ruxolitinib cream in patients with vitiligo and report the efficacy and safety results up to 52 weeks of double-blind treatment.

白癜风是一种慢性自身免疫性疾病，可导致皮肤脱色和生活质量下降。目前尚无批准的治疗白癜风的疗法，目前的非标签疗法疗效有限，急需改进治疗方案。我们研究了鲁索替尼乳膏对白癜风患者的治疗潜力，并报告了为期52周的双盲治疗的有效性和安全性。